A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Celgene
Janssen Research & Development, LLC
Wake Forest University Health Sciences
Pfizer
Institut Cancerologie de l'Ouest
Incyte Corporation
GlaxoSmithKline
Amgen
Amgen
City of Hope Medical Center
Celgene
Duke University
SWOG Cancer Research Network
University of Illinois at Chicago
Pfizer
Altor BioScience
Amgen
Karyopharm Therapeutics Inc
Amgen
pharmaand GmbH
Altor BioScience
Stemline Therapeutics, Inc.
Hellenic Society of Hematology
Antengene Corporation
Takeda
Celgene
H. Lee Moffitt Cancer Center and Research Institute
Hackensack Meridian Health
Amgen
GlaxoSmithKline
Celgene
University of Michigan Rogel Cancer Center
European Society for Blood and Marrow Transplantation
AbbVie
University of Arkansas
Roswell Park Cancer Institute
University of Arkansas
Merck Sharp & Dohme LLC
Boston VA Research Institute, Inc.
Amgen
Masonic Cancer Center, University of Minnesota
Merck Sharp & Dohme LLC
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
Novartis
GlaxoSmithKline
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center